Comprehensive Transcriptome Profiling of Sporadic Medullary Thyroid Carcinomas

Domenico Palumbo1, Viola Melone1, Luigi Palo1,2

  • 1Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081, Baronissi, SA, Italy.

Scientific Data
|January 15, 2026
PubMed

Insights

This study profiled 72 medullary thyroid carcinoma (MTC) tumors, revealing significant molecular heterogeneity. The findings underscore the need for personalized treatment strategies for this rare neuroendocrine neoplasm.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Medullary thyroid carcinoma (MTC) is a rare neuroendocrine neoplasm originating from thyroid C cells.
  • Genetic alterations like RET and RAS mutations occur in 50-80% of sporadic MTCs.
  • Limited transcriptomic data exists, leaving MTC biology and progression mechanisms largely unknown.

Purpose of the Study:

  • To perform transcriptome profiling on a cohort of 72 MTC specimens.
  • To investigate the molecular heterogeneity of MTC.
  • To identify potential molecular targets for personalized treatment strategies.

Main Methods:

  • Transcriptome profiling was conducted on 72 MTC specimens.
  • Analysis focused on patients with diverse genetic backgrounds.
  • Data was analyzed to highlight molecular differences and similarities.

Main Results:

  • Transcriptome profiling revealed significant molecular heterogeneity across MTC specimens.
  • The study identified distinct molecular profiles within the MTC cohort.
  • Genetic background influenced the observed molecular landscape.

Conclusions:

  • Medullary thyroid carcinoma exhibits substantial molecular heterogeneity.
  • Personalized treatment strategies are crucial for effective MTC management.
  • The generated transcriptomic profiles offer new insights into MTC's molecular landscape.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
The Thyroid Gland01:23

The Thyroid Gland

The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
7.1K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
58
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
59